DR. DANIEL A HABER, MD PHD
Osteopathic Medicine in Boston, MA
License number
Massachusetts 54111
Category
Osteopathic Medicine
Type
Internal Medicine
License number
Massachusetts 54111
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
55 7202, Boston, MA 02114
Phone
(617) 726-7805
(617) 724-6919 (Fax)
(617) 724-0287
(617) 726-2894 (Fax)
(617) 724-6919 (Fax)
(617) 724-0287
(617) 726-2894 (Fax)
Organization information
See more information about DANIEL A HABER at bizstanding.comDaniel Haber MD,PHD
55 Fruit St, Boston, MA 02114
Industry:
Internist
Phone:
(617) 726-7805 (Phone)
Daniel Arie Haber
Professional information
Daniel A Haber, Boston MA
Specialties:
Internal Medicine, Medical Oncology, Hematology & Oncology, Hematology, Hematology
Work:
Hematology Oncology Assoc East
100 Blossom St, Boston, MA 02114 Massachusetts General Hospital
55 Fruit St, Boston, MA 02114
100 Blossom St, Boston, MA 02114 Massachusetts General Hospital
55 Fruit St, Boston, MA 02114
Education:
Stanford University (1983)
Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting Treatments
US Patent:
8465916, Jun 18, 2013
Filed:
Aug 20, 2007
Appl. No.:
11/894160
Inventors:
Daphne Winifred Bell - Arlington MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnston - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnston - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US
Assignee:
The General Hospital Corporation - Boston MA
Dana Farber Cancer Institute, Inc. - Boston MA
Dana Farber Cancer Institute, Inc. - Boston MA
International Classification:
C12Q 1/68
US Classification:
435 61
Abstract:
The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting Treatments
US Patent:
8105769, Jan 31, 2012
Filed:
Aug 20, 2007
Appl. No.:
11/894135
Inventors:
Daphne Winifred Bell - Arlington MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnston - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnston - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US
Assignee:
The General Hospital Corporation - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
Downstream Genes Of Tumor Suppressor Wt1
US Patent:
6177248, Jan 23, 2001
Filed:
Feb 24, 1999
Appl. No.:
9/256301
Inventors:
Jonathan Oliner - Mountain View CA
Vivi Truong - San Jose CA
Daniel Haber - Chestnut Hill MA
Sean Lee - Malden MA
Vivi Truong - San Jose CA
Daniel Haber - Chestnut Hill MA
Sean Lee - Malden MA
Assignee:
Affymetrix, Inc. - Santa Clara CA
International Classification:
C12Q 168, C12N 1500, C07H 2102
US Classification:
435 6
Abstract:
Methods are provided for diagnosing cancers, drug-screening, and functionally analyzing mutations involving the WT1 gene. The methods involve use of the newly identified set of genes which are regulated by WT1 as well as by the set of genes which are regulated by WT1 fusions to EWS. Monitoring expression levels of these sets of genes can be used as an indicator of the genetic status of the gene. It can also identify which have similar effects on down-stream genes.
Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting Treatments
US Patent:
7964349, Jun 21, 2011
Filed:
Aug 20, 2007
Appl. No.:
11/894159
Inventors:
Daphne Winifred Bell - Arlington MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnston - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnston - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US
Assignee:
The General Hospital Corporation - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
Expression Monitoring Of Downstream Genes In The Brca1 Pathway
US Patent:
6258536, Jul 10, 2001
Filed:
Dec 1, 1998
Appl. No.:
9/203677
Inventors:
Jonathan Oliner - Mountain View CA
Fred Christians - Los Altos CA
Vivi Truong - San Jose CA
Daniel Haber - Chestnut Hill MA
James Bean - Arlington MA
David Miklos - W. Roxbury MA
Denis Paul Harkin - Belfast BT5 6HX, Northern Ireland, GB
Fred Christians - Los Altos CA
Vivi Truong - San Jose CA
Daniel Haber - Chestnut Hill MA
James Bean - Arlington MA
David Miklos - W. Roxbury MA
Denis Paul Harkin - Belfast BT5 6HX, Northern Ireland, GB
International Classification:
C12Q 168, G01N 3353, C12P 2106, A61K 4900, C07H 2104
US Classification:
435 6
Abstract:
Analysis of the genes whose expression is affected by BRCA1 has identified a set of genes, each of which is up- or down-regulated by BRCA1. Each of these genes, alone or in groups, can be used to determine the mutational status of a BRCA1 gene, to determine whether a particular allelic variant affects BRCA1 function, to diagnose neoplasia, and to help identify candidate drugs which may be useful as anti-neoplastic agents.
Method For Predicting Responsiveness To Drugs
US Patent:
2006024, Nov 2, 2006
Filed:
Apr 5, 2006
Appl. No.:
11/398413
Inventors:
Daniel Haber - Chestnut Hill MA, US
Gromoslaw Smolen - Cambridge MA, US
Gromoslaw Smolen - Cambridge MA, US
Assignee:
The General Hospital Corporation - Boston MA
International Classification:
C12Q 1/68, G01N 33/574
US Classification:
435006000, 435007230
Abstract:
The present invention provides a novel method to determine the likelihood of effectiveness of a treatment in an individual affected with or at risk for developing cancer. The method involves detecting the presence or absence of Met amplification in an individual. The presence of Met amplification indicates that a Met targeting treatment is likely to be effective. Preferably, the Met targeting treatment is PHA-665752 or PF-02341066. In addition, the present methods allow for the detection of cancer in an individual, wherein the presence of Met amplification indicates that cancer is present and further that it will be treatable, namely with a Met targeting treatment.
Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting Treatments
US Patent:
7294468, Nov 13, 2007
Filed:
Dec 5, 2005
Appl. No.:
11/294621
Inventors:
Daphne Winifred Bell - Arlington MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnson - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnson - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US
Assignee:
The General Hospital Corporation - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
C12Q 1/68
US Classification:
435 6, 424 91, 435 912
Abstract:
The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
Dock 3 Tumor Suppressor Gene
US Patent:
2006004, Feb 23, 2006
Filed:
Jun 10, 2002
Appl. No.:
10/480330
Inventors:
Vijay Yajnik - Chestnut Hill MA, US
Charles Paulding - Weymouth MA, US
Andrea McClatchey - Concord MA, US
Daniel Haber - Chestnut Hill MA, US
Charles Paulding - Weymouth MA, US
Andrea McClatchey - Concord MA, US
Daniel Haber - Chestnut Hill MA, US
International Classification:
C07K 14/52, A01K 67/027, C07H 21/02, C12P 21/02
US Classification:
536023100, 530351000, 435069500, 435320100, 435354000, 800018000
Abstract:
The invention relates to a newly identified tumor suppressor gene, designated DOS (for Deleted in Osteosarcoma and alternatively referred to herein as DOCK 3) which has been cloned from human and mouse cells. The DOS nucleic acid and protein molecules and their use in the diagnosing and treating disorders characterized by aberrant DOS molecule expression are described.
Localization And Characterization Of The Wilms' Tumor Gene
US Patent:
6943011, Sep 13, 2005
Filed:
Aug 14, 2001
Appl. No.:
09/929315
Inventors:
Katherine M. Call - Malden MA, US
Thomas M. Glaser - Ann Arbor MI, US
Caryn Y. Ito - Toronto, CA
Alan J. Buckler - Arlington MA, US
Jerry M. Pelletier - Baie-D 'Urfe, CA
Daniel A. Haber - Chestnut Hill MA, US
Elise A. Rose - Oakland CA, US
David E. Housman - Newton MA, US
Wendy Bruening - Lower Gwynedd PA, US
André Darveau - St. Foy, CA
Thomas M. Glaser - Ann Arbor MI, US
Caryn Y. Ito - Toronto, CA
Alan J. Buckler - Arlington MA, US
Jerry M. Pelletier - Baie-D 'Urfe, CA
Daniel A. Haber - Chestnut Hill MA, US
Elise A. Rose - Oakland CA, US
David E. Housman - Newton MA, US
Wendy Bruening - Lower Gwynedd PA, US
André Darveau - St. Foy, CA
Assignee:
Massachusetts Institute of Technology - Cambridge MA
International Classification:
C12N015/00, C07H021/02, C07H021/04
US Classification:
4353201, 536 231, 536 235, 536 241
Abstract:
The Wilms' tumor gene associated with 11p3 locus on the human chromosome, as well as a method of analyzing cells for the gene is described and characterized. The gene encodes a transcription unit approximately 50 kb in size and a mRNA of approximately 3 kb, which is expressed in predominantly in kidney and gonadal tissue. The gene is alternative spliced producing four very similar mRNA transcripts. The polypeptides encoded by the Wilms' tumor DNA includes four “zinc fingers” and a region rich in proline and glutamine, suggesting that the polypeptide has a role in transcription regulation.